2026 Artemetrx State of Specialty Spend and Trend Report Webinar

PSG announces the results of the industry’s go-to report on specialty drug spend and trend.

With specialty drug costs remaining a top concern and a pipeline bursting with breakthrough therapies, payers can’t afford to manage specialty spend with yesterday’s strategies. The 2026 Artemetrx State of Specialty Spend and Trend Report delivers the critical data needed to stay ahead of the curve.

Join our industry experts as they unveil the trends reshaping specialty drug management today. Leveraging real-world pharmacy and medical claims data from our book of business, this webinar is your roadmap to proactive specialty spend control.

Watch the Recording

Key Findings

Specialty Drug Trend: Specialty drug trend remains high but decreased from 12.2% to 10.8% on a gross cost basis
Drivers of Specialty Drug Trend: Claim utilization is now the dominant driver of specialty drug trend as the percentage of members using specialty drugs rose to 5.5%
Top Specialty Drugs by Spend: Humira exited the top 10 specialty drugs by spend as Skyrizi, Dupixent, and Rinvoq climbed up the list
Biosimilars Market Share: The market share for biosimilars grew from 32.2% to 56.3%, led by the impact of Humira and Stelara biosimilars
Non-Specialty Drug Spend and Trend: Spotlight feature reveals 10.4% trend in non-specialty, driven by the diabetes category and GLP-1 medications

Expert insight from our panelists:

Renee Rayburg, RPh

Vice President, Clinical Strategy

Kelly Dean, MBA

Vice President, Analytics

Morgan Lee, PhD, MPH, CPH

Vice President, Research & Marketing